当前位置:主页 > 医学论文 > 药学论文 >

药品参考价格制度典型国家创新药品定价与补偿机制

发布时间:2019-04-27 19:24
【摘要】:当前我国正处于向医保支付价格为核心的药价管理制度的转型时期,本文对该制度框架内国际基本模式之一的参考价格制度下代表性制药强国的创新药价管理进行了国际比较。德、法、加这些典型国家新药的定价和补偿机制都具有定价与医保支付挂钩下的创新激励与支付能力平衡,基于价值评价的分类等级管理,多种定价方式的综合管理策略以及多元参与下的药价决策机制等基本特点。这些为我国创新药品管理的革新提供了重要启示。
[Abstract]:At present, our country is in the transition period of the drug price management system with the core of paying the medical insurance price. This paper makes an international comparison on the innovative drug price management of the representative pharmaceutical power under the reference price system, one of the basic international models within the framework of the system. The pricing and compensation mechanisms of these typical new drugs in Germany, France and Canada all have the balance of innovation incentive and ability to pay under the linkage between pricing and medical insurance payment, and the classification level management based on value evaluation. The comprehensive management strategy of multiple pricing methods and the drug price decision-making mechanism under multi-participation. These provide important enlightenment for the innovation of drug management in our country.
【作者单位】: 南京中医药大学经贸管理学院;
【基金】:国家中医药管理局中医药政策研究项目《中医医疗服务价格政策体系研究》(ZYYP-2015);国家中医药管理局重点学科(中医药管理学)开放课题项目《药品支付基准价格改革问题研究》(ZYYGLX-02)
【分类号】:R951

【参考文献】

相关期刊论文 前10条

1 王雅楠;彭小宸;程s,

本文编号:2467245


资料下载
论文发表

本文链接:https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2467245.html


Copyright(c)文论论文网All Rights Reserved | 网站地图 |

版权申明:资料由用户42cb1***提供,本站仅收录摘要或目录,作者需要删除请E-mail邮箱bigeng88@qq.com